JPWO2020231983A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020231983A5 JPWO2020231983A5 JP2021568170A JP2021568170A JPWO2020231983A5 JP WO2020231983 A5 JPWO2020231983 A5 JP WO2020231983A5 JP 2021568170 A JP2021568170 A JP 2021568170A JP 2021568170 A JP2021568170 A JP 2021568170A JP WO2020231983 A5 JPWO2020231983 A5 JP WO2020231983A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- months
- skin
- composition according
- minutes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 88
- 239000000203 mixture Substances 0.000 claims description 70
- 210000003491 skin Anatomy 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 22
- 230000037303 wrinkles Effects 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 230000001815 facial effect Effects 0.000 claims description 12
- 208000017520 skin disease Diseases 0.000 claims description 12
- 208000035475 disorder Diseases 0.000 claims description 11
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 10
- 208000002193 Pain Diseases 0.000 claims description 10
- 206010025135 lupus erythematosus Diseases 0.000 claims description 10
- 231100000344 non-irritating Toxicity 0.000 claims description 10
- 239000003961 penetration enhancing agent Substances 0.000 claims description 10
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 8
- 239000002537 cosmetic Substances 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 208000035985 Body Odor Diseases 0.000 claims description 7
- 229940125644 antibody drug Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 210000003205 muscle Anatomy 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 210000002374 sebum Anatomy 0.000 claims description 6
- 201000000849 skin cancer Diseases 0.000 claims description 6
- 230000035900 sweating Effects 0.000 claims description 6
- 206010040954 Skin wrinkling Diseases 0.000 claims description 5
- 210000004271 bone marrow stromal cell Anatomy 0.000 claims description 5
- 238000003825 pressing Methods 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 201000004384 Alopecia Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 108010008165 Etanercept Proteins 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 208000021710 Hyperpigmentation disease Diseases 0.000 claims description 4
- 208000026748 Hypopigmentation disease Diseases 0.000 claims description 4
- 208000002260 Keloid Diseases 0.000 claims description 4
- 208000000185 Localized scleroderma Diseases 0.000 claims description 4
- 206010027982 Morphoea Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 208000003782 Raynaud disease Diseases 0.000 claims description 4
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 4
- 241001303601 Rosacea Species 0.000 claims description 4
- 206010039710 Scleroderma Diseases 0.000 claims description 4
- 206010040904 Skin odour abnormal Diseases 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 208000009621 actinic keratosis Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 208000015318 chromhidrosis Diseases 0.000 claims description 4
- 230000037371 chromhidrosis Effects 0.000 claims description 4
- 230000003750 conditioning effect Effects 0.000 claims description 4
- 230000008921 facial expression Effects 0.000 claims description 4
- 230000003676 hair loss Effects 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 230000037315 hyperhidrosis Effects 0.000 claims description 4
- 210000001117 keloid Anatomy 0.000 claims description 4
- 208000016809 linear scleroderma Diseases 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000004700 rosacea Diseases 0.000 claims description 4
- 206010040872 skin infection Diseases 0.000 claims description 4
- 206010055000 Bromhidrosis Diseases 0.000 claims description 3
- 208000019693 Lung disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 241000223503 Platysma Species 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 230000001660 hyperkinetic effect Effects 0.000 claims description 3
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 108030001720 Bontoxilysin Proteins 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 241000193163 Clostridioides difficile Species 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010011659 Cutaneous amyloidosis Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 208000014094 Dystonic disease Diseases 0.000 claims description 2
- 208000004095 Hemifacial Spasm Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 239000004907 Macro-emulsion Substances 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 208000004350 Strabismus Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010042496 Sunburn Diseases 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 229940035674 anesthetics Drugs 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 239000000560 biocompatible material Substances 0.000 claims description 2
- 229940053031 botulinum toxin Drugs 0.000 claims description 2
- 229960002874 briakinumab Drugs 0.000 claims description 2
- 229960003735 brodalumab Drugs 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 229960003115 certolizumab pegol Drugs 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000006111 contracture Diseases 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 210000004207 dermis Anatomy 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 201000004997 drug-induced lupus erythematosus Diseases 0.000 claims description 2
- 208000010118 dystonia Diseases 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 229950010512 fezakinumab Drugs 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000003193 general anesthetic agent Substances 0.000 claims description 2
- 229960001743 golimumab Drugs 0.000 claims description 2
- 229950010864 guselkumab Drugs 0.000 claims description 2
- 210000003780 hair follicle Anatomy 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 208000018360 neuromuscular disease Diseases 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims description 2
- -1 retin A Chemical compound 0.000 claims description 2
- 238000005096 rolling process Methods 0.000 claims description 2
- 210000001732 sebaceous gland Anatomy 0.000 claims description 2
- 229960004540 secukinumab Drugs 0.000 claims description 2
- 229950003804 siplizumab Drugs 0.000 claims description 2
- 208000018198 spasticity Diseases 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 210000000434 stratum corneum Anatomy 0.000 claims description 2
- 230000036561 sun exposure Effects 0.000 claims description 2
- 210000000106 sweat gland Anatomy 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 229960003824 ustekinumab Drugs 0.000 claims description 2
- 229950009002 zanolimumab Drugs 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010020651 Hyperkinesia Diseases 0.000 claims 1
- 208000000269 Hyperkinesis Diseases 0.000 claims 1
- 206010062575 Muscle contracture Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 238000007373 indentation Methods 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000012935 Averaging Methods 0.000 description 6
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000950638 Symphysodon discus Species 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- HOQADATXFBOEGG-UHFFFAOYSA-N isofenphos Chemical compound CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C HOQADATXFBOEGG-UHFFFAOYSA-N 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025077186A JP2025118791A (ja) | 2019-05-14 | 2025-05-07 | ピーク効果の遅延および／または応答持続時間の延長 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847901P | 2019-05-14 | 2019-05-14 | |
| US62/847,901 | 2019-05-14 | ||
| PCT/US2020/032458 WO2020231983A1 (en) | 2019-05-14 | 2020-05-12 | Delaying peak effect and/or extending duration of response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077186A Division JP2025118791A (ja) | 2019-05-14 | 2025-05-07 | ピーク効果の遅延および／または応答持続時間の延長 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022533113A JP2022533113A (ja) | 2022-07-21 |
| JPWO2020231983A5 true JPWO2020231983A5 (enExample) | 2023-05-12 |
Family
ID=71094800
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568170A Pending JP2022533113A (ja) | 2019-05-14 | 2020-05-12 | ピーク効果の遅延および／または応答持続時間の延長 |
| JP2025077186A Pending JP2025118791A (ja) | 2019-05-14 | 2025-05-07 | ピーク効果の遅延および／または応答持続時間の延長 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077186A Pending JP2025118791A (ja) | 2019-05-14 | 2025-05-07 | ピーク効果の遅延および／または応答持続時間の延長 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220296503A1 (enExample) |
| EP (1) | EP3969038A1 (enExample) |
| JP (2) | JP2022533113A (enExample) |
| KR (1) | KR20220008311A (enExample) |
| CN (2) | CN120919032A (enExample) |
| AU (1) | AU2020274082A1 (enExample) |
| BR (1) | BR112021022619A2 (enExample) |
| CA (1) | CA3139983A1 (enExample) |
| IL (1) | IL287988A (enExample) |
| MX (1) | MX2021012739A (enExample) |
| SG (1) | SG11202110518XA (enExample) |
| WO (1) | WO2020231983A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019010131A2 (pt) | 2016-11-21 | 2019-10-08 | Eirion Therapeutics Inc | entrega transdérmica de agentes grandes |
| CN116925213B (zh) * | 2023-09-12 | 2024-03-15 | 中国人民解放军军事科学院军事医学研究院 | 一种中和a型肉毒毒素的纳米抗体 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US296006A (en) | 1884-04-01 | John hoefleb | ||
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US6939852B2 (en) | 1991-09-24 | 2005-09-06 | Allergan, Inc. | Methods and compositions for the treatment of cerebral palsy |
| US7384918B2 (en) | 1991-09-24 | 2008-06-10 | Allergan, Inc. | Botulinum toxin for treating muscle contracture |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US6010715A (en) | 1992-04-01 | 2000-01-04 | Bertek, Inc. | Transdermal patch incorporating a polymer film incorporated with an active agent |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1261849B (it) | 1993-09-02 | 1996-06-03 | Avantgarde Spa | Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici. |
| US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US5965154A (en) | 1998-03-17 | 1999-10-12 | Plc Holding, L.L.C. | Adhesive matrix type transdermal patch and method of manufacturing same |
| US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
| US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
| US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| SG160358A1 (en) | 2005-03-03 | 2010-04-29 | Revance Therapeutics Inc | Compositions and methods for topical application and transdermal delivery of an oligopeptide |
| MX2008006750A (es) | 2005-12-01 | 2008-09-03 | Univ Massachusetts Lowell | Nanoemulsiones de botulinum. |
| EP2015773A4 (en) | 2006-04-27 | 2010-05-05 | Anterios Inc | EXAMINATION OF THE EFFECTS OF TOPICAL ADMINISTRATION OF CHEMICALLY DENOMINATING PHARMACEUTICALS |
| US20120150023A1 (en) | 2007-08-06 | 2012-06-14 | Kaspar Roger L | Microneedle arrays for active agent delivery |
| WO2010056922A2 (en) * | 2008-11-12 | 2010-05-20 | Kythera Biopharmaceuticals, Inc. | Systems and methods for delivery of biologically active agents |
| SG10201405582YA (en) | 2008-12-31 | 2014-10-30 | Revance Therapeutics Inc | Injectable Botulinum Toxin Formulations |
| SG10201804552WA (en) | 2011-01-24 | 2018-07-30 | Anterios Inc | Nanoparticle compositions, formulations thereof, and uses therefor |
| WO2012103035A1 (en) | 2011-01-24 | 2012-08-02 | Anterios, Inc. | Nanoparticle compositions |
| EP2793869B1 (en) | 2011-12-21 | 2015-09-23 | 3M Innovative Properties Company | Transdermal adhesive patch assembly with removable microneedle array and method of using same |
| WO2015020982A2 (en) * | 2013-08-04 | 2015-02-12 | Aquavit Pharmaceuticals, Inc. | Direct application system and method for the delivery of bioactive compositions and formulations |
| JP6955491B2 (ja) * | 2015-10-29 | 2021-10-27 | ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法 |
| US20170209553A1 (en) * | 2016-01-22 | 2017-07-27 | Transderm, Inc. | Delivery of botulinum with microneedle arrays |
| BR112019010131A2 (pt) * | 2016-11-21 | 2019-10-08 | Eirion Therapeutics Inc | entrega transdérmica de agentes grandes |
| WO2018151832A1 (en) | 2017-02-17 | 2018-08-23 | Allergan, Inc. | Microneedle array with active ingredient |
-
2020
- 2020-05-12 CA CA3139983A patent/CA3139983A1/en active Pending
- 2020-05-12 CN CN202511054670.6A patent/CN120919032A/zh active Pending
- 2020-05-12 MX MX2021012739A patent/MX2021012739A/es unknown
- 2020-05-12 CN CN202080036448.2A patent/CN114173808A/zh active Pending
- 2020-05-12 WO PCT/US2020/032458 patent/WO2020231983A1/en not_active Ceased
- 2020-05-12 SG SG11202110518XA patent/SG11202110518XA/en unknown
- 2020-05-12 AU AU2020274082A patent/AU2020274082A1/en active Pending
- 2020-05-12 KR KR1020217040671A patent/KR20220008311A/ko active Pending
- 2020-05-12 BR BR112021022619A patent/BR112021022619A2/pt unknown
- 2020-05-12 EP EP20733076.2A patent/EP3969038A1/en active Pending
- 2020-05-12 JP JP2021568170A patent/JP2022533113A/ja active Pending
- 2020-05-12 US US17/610,057 patent/US20220296503A1/en active Pending
-
2021
- 2021-11-10 IL IL287988A patent/IL287988A/en unknown
-
2025
- 2025-05-07 JP JP2025077186A patent/JP2025118791A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022164750A5 (enExample) | ||
| JP2019535829A5 (enExample) | ||
| Huang et al. | Research progress on cosmetic microneedle systems: Preparation, property and application | |
| US20220218623A1 (en) | Transdermal delivery of large agents | |
| JP2014528900A5 (enExample) | ||
| JP2013534842A (ja) | 皮膚ケア製品の送達 | |
| AU2025226856A1 (en) | Improved Delivery of Large Agents | |
| JPWO2020231983A5 (enExample) | ||
| JP2025118791A (ja) | ピーク効果の遅延および／または応答持続時間の延長 | |
| JPWO2018093465A5 (enExample) | ||
| CN117143164A (zh) | 一种腺苷共晶体及其制备方法和应用 | |
| KR101480164B1 (ko) | 쿠라리논 또는 고삼추출물을 포함하는 피부질환 예방 및 개선용 화장료 조성물 | |
| CN120302959A (zh) | 修饰肽、组合物、抑制肌肉细胞收缩的方法、改善皮肤的方法和修饰肽的用途 | |
| CN1031744C (zh) | 一种磁渗药膏的制备方法 | |
| Ryu et al. | 26551 Photothermal therapy using gold nanoparticles on the acne in Asians: Preliminary study | |
| Ma et al. | MALDI-TOF evidence of GDP20 antibacterial activity against Cutibacterium acnes | |
| HK40070640A (en) | Delaying peak effect and/or extending duration of response | |
| HK40060152A (en) | Improved delivery of large agents | |
| Rygg et al. | Fixed-Combination Halobetasol Propionate and Tazarotene Lotion Reduces Signs and Symptoms of Psoriasis in Patients With Body Surface Area Involvement of 3% to 5% | |
| Finstad et al. | 26549 Risk of malignancy associated with medication use in elderly patients with psoriasis | |
| HK40013656A (en) | Transdermal delivery of large agents | |
| CN114668708A (zh) | 一种人体穴位按摩用调理液 | |
| JP2012025720A (ja) | セラミド合成促進剤、化粧料、皮膚外用剤、医薬部外品、医薬品およびセラミド合成促進剤の製造方法 |